title: The Effect of CRH, Dexamethasone and Naltrexone on the Mu, Delta and Kappa Opioid Receptor Agonist Binding in Lamb Hypothalamic-Pituitary-Adrenal Axis.
abstract: The aim of the study was to evaluate changes in the opioid receptor binding (mu, delta and kappa) in the hypothalamus, anterior pituitary and adrenal cortex (HPA) of lambs treated in vivo with corticotrophin releasing hormone (CRH), naltrexone, an opioid receptor antagonist (NAL), and dexamethasone, a potent cortisol analog (DEX). Experiment was carried out on 3 months old female lambs of polish mountain strain. Lambs received a single i.v. injection of NaCl (control), CRH (alone or in combination with naltrexone), naltrexone or dexamethasone. One hour later animals were decapitated under anaesthesia, tissues were dissected out and receptor binding assays were performed with radioligands for each type of opioid receptors--3H-DAGO, 3H-DPDPE and 3H-EKC for mu, delta and kappa receptor, respectively. Coexistence of specific binding sites for each type of opioid receptor was demonstrated in all levels of HPA axis of control lambs, however their distribution was uneven. Acute treatment with CRH, DEX and NAL caused downregulation or upregulation of mu, delta, kappa receptor binding in each level of HPA axis. CRH effects on mu, delta and kappa opioid receptor binding varied within the HPA axis and were modulated by naltrexone. Treatment with naltrexone increased in vitro mu, delta and kappa receptor binding in most tested structures except delta receptor binding in adrenal (decrease by 52%) and kappa receptor binding in pituitary (decrease by 41%). Dexamethasone significantly decreased the mu, delta and kappa opioid receptor binding in adrenal cortex but differentially affected opioid receptor binding in hypothalamus and pituitary. It seems probable that endogenous opioid peptides acting through mu, delta and kappa receptors interact with the hormones released from the hypothalamic-pituitary-adrenal axis in physiological and pathophysiological situations.
authors.forename: Krystyna
authors.initials: K
authors.lastname: Pierzchała-Koziec
authors.forename: Marta
authors.initials: M
authors.lastname: Dziedzicka-Wasylewska
authors.forename: Peter
authors.initials: P
authors.lastname: Oeltgen
authors.forename: Joanna
authors.initials: J
authors.lastname: Zubel-Łojek
authors.forename: Anna
authors.initials: A
authors.lastname: Latacz
authors.forename: Ewa
authors.initials: E
authors.lastname: Ocłon
mesh_terms: D000818:Animals; D003346:Corticotropin-Releasing Hormone / Q000502:physiology*; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D009271:Naltrexone / Q000494:pharmacology*; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011957:Receptors, Opioid / Q000819:agonists*; D012756:Sheep
chemical_list: D011957:Receptors, Opioid; D009271:Naltrexone; D003907:Dexamethasone; D003346:Corticotropin-Releasing Hormone